Daratumumab serum concentrations with single vs split first dose in the all treated population
| . | Postfirst dose . | C3 D1 preinfusion . | C3 D1 end of infusion . | |
|---|---|---|---|---|
| C1 D1 end of infusion . | C1 D2 end of infusion . | |||
| Single first dose | ||||
| Patients, n | 8 | — | 9 | 9 |
| Mean daratumumab serum concentration, μg/mL (SD) | 321.14 (49.0) | 517.46 (137.2) | 895.61 (169.5) | |
| CV, % | 15.3 | — | 26.5 | 18.9 |
| Geometric mean daratumumab serum concentration, μg/mL | 317.73 | 502.54 | 882.53 | |
| Split first dose | ||||
| Patients, n | — | 69 | 52 | 52 |
| Mean daratumumab serum concentration, μg/mL (SD) | 255.03 (71.87) | 618.53 (256.2) | 951.44 (350.1) | |
| CV, % | — | 28.2 | 41.4 | 36.8 |
| Geometric mean daratumumab serum concentration, μg/mL | 244.90 | 549.57 | 855.74 | |
| . | Postfirst dose . | C3 D1 preinfusion . | C3 D1 end of infusion . | |
|---|---|---|---|---|
| C1 D1 end of infusion . | C1 D2 end of infusion . | |||
| Single first dose | ||||
| Patients, n | 8 | — | 9 | 9 |
| Mean daratumumab serum concentration, μg/mL (SD) | 321.14 (49.0) | 517.46 (137.2) | 895.61 (169.5) | |
| CV, % | 15.3 | — | 26.5 | 18.9 |
| Geometric mean daratumumab serum concentration, μg/mL | 317.73 | 502.54 | 882.53 | |
| Split first dose | ||||
| Patients, n | — | 69 | 52 | 52 |
| Mean daratumumab serum concentration, μg/mL (SD) | 255.03 (71.87) | 618.53 (256.2) | 951.44 (350.1) | |
| CV, % | — | 28.2 | 41.4 | 36.8 |
| Geometric mean daratumumab serum concentration, μg/mL | 244.90 | 549.57 | 855.74 | |
C, cycle; CV, coefficient of variation; D, day; SD, standard deviation.